FOLH1 and metastatic prostate carcinoma: In this case, if not for histologic confirmation, the patient may have been classified as stage IV in the presence of a presumed PSMA-avid distant metastasis, and thus denied curative intent therapy to an otherwise localized prostate cancer, and also be subject to highly toxic life-long androgen deprivation therapy as the standard of care for metastatic prostate cancer.